Tarbox Family Office’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-148
Closed -$19K 370
2022
Q1
$19K Sell
148
-124
-46% -$13.6K ﹤0.01% 285
2021
Q4
$37K Buy
272
+36
+15% +$5.17K 0.01% 261
2021
Q3
$32K Buy
236
+64
+37% +$8.07K 0.01% 303
2021
Q2
$18K Buy
172
+40
+30% +$3.84K ﹤0.01% 389
2021
Q1
$12K Buy
132
+100
+313% +$9.39K ﹤0.01% 387
2020
Q4
$3K Sell
32
-128
-80% -$11.4K ﹤0.01% 674
2020
Q3
$16K Buy
160
+144
+900% +$15K ﹤0.01% 311
2020
Q2
$2K Hold
16
﹤0.01% 740
2020
Q1
$1K Buy
+16
New +$996 ﹤0.01% 838
2017
Q3
Sell
-52
Closed -$1K 603
2017
Q2
$1K Buy
+52
New +$960 ﹤0.01% 524

Other funds holding DXCM

Tarbox Family Office's DXCM Position: Q2 2022 in Review

Tarbox Family Office sold out of DexCom (DXCM) in Q2 2022, closing a stake of 148 shares — an estimated $19K sold.

Tarbox Family Office first reported a position in DXCM in Q2 2017 and held it in 10 quarters. The position peaked at $37K in Q4 2021. 797 funds tracked by Wall St. Rank hold DXCM as of Q2 2022.

  • Tarbox Family Office reported no remaining DexCom position as of Q2 2022 after selling out during the quarter.
  • Tarbox Family Office sold 148 DexCom shares in Q2 2022, an estimated $19K.
  • Tarbox Family Office first reported a position in DexCom in Q2 2017 and held it in 10 quarters.
  • Tarbox Family Office's DexCom position peaked at $37K in Q4 2021.
  • 797 funds tracked by Wall St. Rank held DexCom as of Q2 2022.

Based on Tarbox Family Office's 13F filing for Q2 2022, filed 19 Jul 2022.